NCT02520427View on ClinicalTrials.gov

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 9, 2022

Study Completion Date

January 9, 2022

Conditions
Relapsed/Refractory AMLMinimal Residual Disease Positive AMLMyelodysplastic Syndrome
Interventions
DRUG

AMG 330

0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.

Trial Locations (11)

24105

Universitätsklinikum Schleswig-Holstein, Kiel

27157

Wake Forest University Health Sciences, Winston-Salem

77030

University of Texas MD Anderson Cancer Center, Houston

81377

Klinikum der Universität München Campus Grosshadern, München

89081

Universitatsklinikum Ulm, Ulm

91010

Research Site, Duarte

98109

Seattle Cancer Care Alliance, Seattle

35294-3300

University of Alabama at Birmingham, Birmingham

M5G 2M9

Princess Margaret Cancer Centre, Toronto

1007 MB

Research Site, Amsterdam

3015 CE

Erasmus Medisch Centrum, Rotterdam

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02520427 - A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies | Biotech Hunter | Biotech Hunter